Shares of Candel Therapeutics Inc. (CADL) surged over 9% on Friday morning, reaching their highest level in nearly a month ...

Century Therapeutics, Candel Therapeutics and MacroGenics have all used their third-quarter earnings releases to disclose how they’re fine-tuning their clinical pipelines to conserve cash. Century has ...

Shares of Candel Therapeutics Inc. surged nearly 10% on Wednesday and extended gains in after-hours trading following a ...

With the business potentially at an important milestone, we thought we'd take a closer look at Candel Therapeutics, Inc.'s ...

Candel Therapeutics' CAN-2409 shows robust, multi-cancer efficacy with significant survival gains in prostate, pancreatic, and lung cancers, plus promising early glioblastoma data. The company is ...

Candel Therapeutics, Inc. (NASDAQ:CADL) shares are trading higher Thursday after the company received FDA orphan drug designation for CAN-2409 for the treatment of pancreatic cancer. "We recently ...

Full abstracts will be released by ASCO on Thursday, May 22, 2025, at 5:00 PM ET. Details from the presentations will be available following the event on the Candel website at Candel Media. * Dr.

Candel Therapeutics is taking difficult measures to keep its clinical flame burning, laying off 50% of its team as part of a wide scale restructuring meant to save cash for a couple of core programs.

An announcement from Candel Therapeutics ( (CADL)) is now available. Candel Therapeutics has reported promising results from its ongoing phase 1b clinical trial of CAN-3110 in recurrent high-grade ...

NEEDHAM, Mass., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal ...

Candel Therapeutics, Inc. has announced an underwritten public offering to raise $80 million through the sale of its common stock and pre-funded warrants. The company plans to use the proceeds to ...